Standardization and individualization of PRRT: Bodei and colleagues focus on standardization of peptide receptor radionuclide therapy as a starting point for redefining the paradigm from a one-size-fits-all approach to personalized treatment.
Page 1753
PET/CT in GEP neuroendocrine neoplasms: Schillaci provides an overview of the current and potential roles of PET/CT in guiding patient management in gastroenteropancreatic neuroendocrine neoplasms and previews an article on this topic in this issue of JNM.
Page 1757
124I PET and response in DTC: Jentzen and colleagues analyze 124I PET/CT imaging data from patients with differentiated thyroid cancer to assess relationships between absorbed radiation dose to lesions and response after radioiodine therapy.
Page 1759
18F-FDG accumulation and LDHA expression: Zhou and colleagues investigate the relationship between lactate dehydrogenase A and tracer accumulation on 18F-FDG PET imaging in patients with lung adenocarcinomas.
Page 1766
Parametric methods for 18F-FAZA: Verwer and colleagues determine the validity of parametric methods for quantification of this hypoxia-specific PET tracer with potential for, among other applications, early response monitoring and radiation therapy dose painting.
Page 1772
d-18F-FMT clinical results: Burger and colleagues demonstrate tumor detection with PET using this novel radiolabeled tyrosine derivative in patients with non–small cell lung and head and neck squamous cell cancers and compare results with those from 18F-FDG.
Page 1778
PET and NETs: Bahri and colleague assess the long-term prognostic utility of 18F-FDG PET for patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Page 1786
99mTc-PSMA inhibitors for prostate cancer: Vallabhajosula and colleagues offer first human data on a novel 99mTc-labeled small-molecule prostate-specific membrane antigen inhibitor that binds with high affinity to PSMA-positive tumor cells in vitro and localizes in prostate cancer xenografts.
Page 1791
Sentinel nodes in ovarian cancer: Kleppe and colleagues explore the feasibility of the sentinel node technique in ovarian cancer with tracer injection into the ovarian ligaments and evaluate the safety of the procedure for health care workers.
Page 1799
Brain glucose metabolism and neurocognition in ALL: Krull and colleagues examine associations between regional brain metabolism, as measured by 18F-FDG PET, and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation.
Page 1805
PET tracer choice in GEPNETs: Has Simsek and colleagues compare 68Ga-DOTATATE and 18F-FDG PET/CT in gastroenteropancreatic neuroendocrine tumors and look at complementarities between PET/CT results and histopathologic findings in therapy management, particularly in intermediate-grade patients.
Page 1811
11C-donepezil PET: Gjerløff and colleagues evaluate the utility of 11C-donepezil for PET imaging of acetylcholinesterase densities in peripheral organs, including the salivary glands, heart, stomach, intestine, pancreas, liver, and spleen.
Page 1818
MR AC for brain PET/MR: Izquierdo-Garcia and colleagues describe a new approach for head MR-based attenuation correction with statistical parametric mapping, combining segmentation- and atlas-based features to generate attenuation maps for integrated PET/MR imaging.
Page 1825
Imaging of ischemic stroke: Heiss presents a broad educational overview of clinical applications of radionuclide imaging in the management of stroke, including both limitations and promising future perspectives.
Page 1831
188Re-labeled Affibody molecule: Altai and colleagues assess the feasibility of 188Re-ZHER2:V2 as a potential candidate agent for radionuclide therapy of human epidermal growth factor receptor type 2–expressing tumors.
Page 1842
Monitoring response with 111In-RGD2: Terry and colleagues evaluate in animal studies the potential of this RGD-based imaging tracer, which allows specific imaging of integrin αvβ3 expression, to monitor early responses to antiangiogenic or radiation therapy.
Page 1849
LLP2A conjugates for melanoma imaging: Beaino and Anderson assess in a murine model 2 radiolabeled conjugates of a high-affinity integrin α4β1 peptidomimetic ligand for PET/CT imaging in subcutaneous and metastatic melanoma tumors.
Page 1856
188Re-PEGylated liposomes in NSCLC: Lin and colleagues investigate the biodistribution, pharmacokinetics, and therapeutic efficacy of novel nanoradiopharmaceuticals on non–small cell lung cancer using a xenograft lung tumor model and reporter gene imaging techniques.
Page 1864
Lung metabolism in experimental ARDS: Prost and colleagues ask how local 18F-FDG phosphorylation rate and volume of distribution are related to initial regional inflammatory response during early acute lung injury and to specific mechanisms of injury.
Page 1871
Monitoring bevacizumab therapy: Rylova and colleagues use histologic techniques and molecular imaging with PET and 68Ga-NODAGA-c(RGDfK) to follow bevacizumab treatment of squamous cell carcinoma xenografts to determine whether αvβ3 integrin imaging can monitor tumor angiogenesis.
Page 1878
(−)-18F-flubatine dosimetry: Sattler and colleagues detail organ doses and effective doses of this promising PET tracer for neuroimaging of nicotinic α4β2 acetylcholine receptors in animals and human volunteers.
Page 1885
LED device for PIT: de Boer and colleagues describe the development of a light-emitting diode photoimmunotherapy device, including validation of feasibility, applicability, safety, and consistency of the system for cancer treatment.
Page 1893
Microscopic optical and nuclear validation: Inoue and colleagues develop a fiducial marker simultaneously compatible with 2-color near-infrared fluorescence autoradiography and conventional hematoxylin–eosin histology to explore the molecular and cellular bases for radioscintigraphic signals in macroscopic in vivo imaging.
Page 1899
Cerenkov luminescence imaging of β-emitters: Carpenter and colleagues investigate improvements in sensitivity of Cerenkov luminescence endoscopy with a β− radiotracer providing both higher β-particle energy and lower γ noise in the imaging optics.
Page 1905
Separation of 99mTc from molybdenum: Bénard and colleagues describe a simple kit-based approach for purification of pertechnetate (99mTcO4−) from solutions with high MoO42− content.
Page 1910
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.